Philip Drake May 30, 2017 Kevetrin Cellceutix Anti-Cancer Drug Candidate’s p53 Activity in Acute Myeloid Leukemia to be Presented by Independent Researchers at the 2017 European Hematology Association Annual Meeting
Philip Drake May 18, 2017 Brilacidin Cellceutix Completes Patient Enrollment of Final Cohort in Phase 2 Trial of Brilacidin for Inflammatory Bowel Disease; Topline Results Anticipated in July
Philip Drake May 10, 2017 Corporate Cellceutix Provides Corporate Update; Significant Milestones Ahead as Multiple Mid-Phase Clinical Trials Set to Conclude
Philip Drake April 19, 2017 Corporate Cellceutix Announces Details for Upcoming Shareholder and Investor Presentations
Philip Drake April 10, 2017 Brilacidin Cellceutix CEO Discusses Brilacidin Following Interim Trial Results for Treating Oral Mucositis and Inflammatory Bowel Disease
Philip Drake March 21, 2017 Brilacidin Cellceutix Releases Favorable Topline Findings as Part of Interim Analysis of Phase 2 Drug Candidate Brilacidin for the Treatment of Inflammatory Bowel Disease
Philip Drake March 16, 2017 Brilacidin Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential Novel Non-Biologic Therapy in Treating Inflammatory Bowel Disease
Philip Drake March 8, 2017 Brilacidin Cellceutix Releases Preliminary Efficacy and Safety Data in Interim Analysis of First Two Cohorts in Phase 2 Trial of Brilacidin for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis
Philip Drake March 3, 2017 Kevetrin Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent
Philip Drake February 22, 2017 Brilacidin Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis
Philip Drake February 16, 2017 Corporate Cellceutix Reports on Q2 Fiscal 2017, Prepares for Important Clinical Milestones
Philip Drake February 10, 2017 Kevetrin Cellceutix Announces Initiation of Main Clinical Site for Phase 2a Trial of p53 Drug Candidate Kevetrin in the Treatment of Platinum-Resistant/Refractory Ovarian Cancer
Philip Drake January 23, 2017 Brilacidin Cellceutix’s Brilacidin Demonstrates Promise in Treating Ulcerative Colitis Supported by Endoscopic Assessment, Patient-Reported Outcomes
Philip Drake January 17, 2017 Corporate Cellceutix Strongly Denounces Criminal Enterprise Mako Research, Who Published “Fake News” Full of Lies and Innuendo
Philip Drake January 17, 2017 Brilacidin Cellceutix Completes Enrollment in Second of Three Planned Cohorts in Phase 2 Clinical Trial of Brilacidin for Inflammatory Bowel Disease
Philip Drake January 4, 2017 Corporate, Brilacidin Cellceutix to Present at Biotech Showcase 2017; Brilacidin for Oral Mucositis Nears Interim Results
Philip Drake December 22, 2016 Corporate Cellceutix Wishes Shareholders Happy Holidays, Prepares for 2017 Focused on Partnerships
Philip Drake December 19, 2016 Prurisol Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol Treatment of Moderate-To-Severe Psoriasis Initiated and Open for Screening
Philip Drake December 15, 2016 Kevetrin Cellceutix Reports Advances in Developing Kevetrin as an Oral Ovarian Cancer Treatment; Company Seeks to Develop World’s First p53-Modulating Oral Cancer Drug
Philip Drake December 7, 2016 Brilacidin Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis
